| Detailed information |
|---|
| CancerLivER ID | 2094 |
| Biomarker | miR-222 |
| Biomarker Name/Symbol (given in Publication) | miR-222 (at a cutoff value of 1.405) |
| Biomolecule | miRNA |
| Subject | Human |
| Degree of Validity | Potential biomarker of chronic HCV; but not validated on independent dataset |
| Experimental Condition | Cancer v/s Normal |
| Cancer type | HCV (Hepatitis C Viral infection) |
| Regulation | Upregulatd in chronic HCV v/s healthy control (with log fold change 3.11) |
| Level of significance | p < 0.01 |
| Source | Serum |
| PMID | 26812693 |
| Type of Biomarker | Diagnostic |
| Pathway | Signaling pathways ,CDK4 translation |
| Cohort | 40 patients with chronic HCV (male = 28 and female = 12) and 60 patients with liver cancer (male = 50 and female = 10) and 30 matched healthy controls. |
| Sensitivity | 80 % |
| Specificity | 90% |
| Accuracy | NA |
| AUC | 0.804 (95 % CI 0.689-0.919) |
| Disease | Human HCV |
| Year of Publication | 2016 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT02928627 |